risankizumab

This page shows the latest risankizumab news and features for those working in and with pharma, biotech and healthcare.

AbbVie lauds head-to-head win for Skyrizi versus Cosentyx

Skyrizi. The head-to-head study pitted IL-23 antagonist Skyrizi (risankizumab) against Novartis’ blockbuster IL-17 inhibitor Cosentyx (secukinumab) – which has sales currently running at around $1bn a quarter – and

Latest news

AbbVie’s JAK inhibitor Rinvoq approved in EU for rheumatoid arthritis

The pharma company has been pushing Rinvoq (upadacitinib) into the RA market, while its Boehringer Ingelheim-partnered drug Skyrizi (risankizumab) has been making headway in psoriasis.
J&J splashes $750m on anti-inflammatory drug bermekimab

secukinumab) and AbbVie’s Skyrizi (risankizumab).
Novartis’ Cosentyx misses the mark in Humira head-to-head

This includes Johnson &Johnson’s Tremfya (guselkumab), AbbVie’s Skyrizi (risankizumab), Eli Lilly’s Taltz (ixekizumab) and Pfizer’s Xeljanz (tofacitinib citrate).
Janssen files Tremfya for psoriatic arthritis in Europe

That could extend the drug’s lead in Europe over its main rival in the class, AbbVie’s Skyrizi (risankizumab), which was approved in Europe for psoriasis earlier this year.
Novartis eyes potential new indication for Cosentyx

This includes Johnson &Johnson’s Tremfya (guselkumab), AbbVie’s Skyrizi (risankizumab), Eli Lilly’s Taltz (ixekizumab) and Pfizer’s Xeljanz (tofacitinib citrate).

More from news
Approximately 3 fully matching, plus 24 partially matching documents found.

Latest Intelligence

Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

Sales are projected at $1.93bn for 2013. Skyrizi (risankizumab) treats psoriasis.
Drug launches to watch in 2019

It announced the filing of upadacitinib in the US and Europe on 20 December, with the filing of risankizumab expected early this year. ... The analysis showed that 56% of patients on risankizumab were symptom-free after a year’s treatment, compared to

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Principal Medical Writer: £48 - 58, 000 according to skills and experience benefits

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Senior Medical Writer, MedComms Agency: Salary TBC

Account Director or Senior Account Director: Salary TBC

Account Manager– Medical Communications: (Negotiable - depending on experience)

Consultant: competitive salary

Director of Scientific Services, Medical Communications, Six fig...: Six figure salary

Vice President: Competitive Salary Offered

Subscribe to our email news alerts

PMHub

Add my company

Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

How do companies prepare for reimbursement?: Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
Integrating electronic health records into clinical trials: How organisations are working to realise the research potential of EHRs...
Keeping up the fight against HIV and using the lessons to tackle other threats: Danny Buckland interviews Gilead’s Mike Elliott...